Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Ovarian Hyperstimulation syndrome: pathophysiology and prevention (2010)

  • Authors:
  • USP affiliated authors: FERRIANI, RUI ALBERTO - FMRP
  • USP Schools: FMRP
  • DOI: 10.1007/s10815-010-9387-6
  • Subjects: TÉCNICAS DE REPRODUÇÃO; DOENÇAS OVARIANAS
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s10815-010-9387-6 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: green
    Informações sobre o Citescore
  • Título: Journal of Assisted Reproduction and Genetics

    ISSN: 1058-0468

    Citescore - 2017: 2.49

    SJR - 2017: 1.179

    SNIP - 2017: 0.951


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FMRP1998619pcd 1998619 estantes deslizantes
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      NASTRI, Carolina O.; FERRIANI, Rui Alberto; ROCHA, Isa A.; MARTINS, Wellington P. Ovarian Hyperstimulation syndrome: pathophysiology and prevention. Journal of Assisted Reproduction and Genetics, New York, v. 27, n. 2/3, p. 121-128, 2010. DOI: 10.1007/s10815-010-9387-6.
    • APA

      Nastri, C. O., Ferriani, R. A., Rocha, I. A., & Martins, W. P. (2010). Ovarian Hyperstimulation syndrome: pathophysiology and prevention. Journal of Assisted Reproduction and Genetics, 27( 2/3), 121-128. doi:10.1007/s10815-010-9387-6
    • NLM

      Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian Hyperstimulation syndrome: pathophysiology and prevention. Journal of Assisted Reproduction and Genetics. 2010 ; 27( 2/3): 121-128.
    • Vancouver

      Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian Hyperstimulation syndrome: pathophysiology and prevention. Journal of Assisted Reproduction and Genetics. 2010 ; 27( 2/3): 121-128.

    Referências citadas na obra
    Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Updat. 2002;8:559–77.
    Vlahos NF, Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci. 2006;1092:247–64.
    Gera PS, Tatpati LL, Allemand MC, Wentworth MA, Coddington CC. Ovarian hyperstimulation syndrome: steps to maximize success and minimize effect for assisted reproductive outcome. Fertil Steril. 2009.
    Michaelson-Cohen R, Altarescu G, Beller U, Reens R, Halevy-Shalem T, Eldar-Geva T. Does elevated human chorionic gonadotropin alone trigger spontaneous ovarian hyperstimulation syndrome? Fertil Steril. 2008;90:1869–74.
    ASRM. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90:S188–93.
    Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Updat. 2003;9:275–89.
    Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 1995;63:268–72.
    Tollan A, Holst N, Forsdahl F, Fadnes HO, Oian P, Maltau JM. Transcapillary fluid dynamics during ovarian stimulation for in vitro fertilization. Am J Obstet Gynecol. 1990;162:554–8.
    Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod. 1991;6:1395–9.
    Pellicer A, Miro F, Sampaio M, Gomez E, Bonilla-Musoles FM. In vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17, 20-desmolase deficiency. Fertil Steril. 1991;55:970–5.
    Soares SR, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Updat. 2008;14:321–33.
    Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Updat. 1997;3:255–66.
    Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A, et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril. 1987;48:57–61.
    Blankestijn PJ, Derkx FH, Van Geelen JA, De Jong FH, Schalekamp MA. Increase in plasma prorenin during the menstrual cycle of a bilaterally nephrectomized woman. Br J Obstet Gynaecol. 1990;97:1038–42.
    Fernandez LA, Tarlatzis BC, Rzasa PJ, Caride VJ, Laufer N, Negro-Vilar AF, et al. Renin-like activity in ovarian follicular fluid. Fertil Steril. 1985;44:219–23.
    Morris RS, Paulson RJ. Increased angiotensin-converting enzyme activity in a patient with severe ovarian hyperstimulation syndrome. Fertil Steril. 1999;71:562–3.
    Manno M, Tomei F. Renin-angiotensin system activation during severe OHSS: cause or effect? Fertil Steril. 2008;89:488.
    McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning Jr RV, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994;344:235–6.
    Gomez R, Simon C, Remohi J, Pellicer A. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod. 2003;68:2164–71.
    Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab. 2002;87:3300–8.
    Villasante A, Pacheco A, Ruiz A, Pellicer A, Garcia-Velasco JA. Vascular endothelial cadherin regulates vascular permeability: Implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2007;92:314–21.
    Rodewald M, Herr D, Duncan WC, Fraser HM, Hack G, Konrad R, et al. Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum Reprod. 2009;24(5):1191–9.
    Nardo LG, Cheema P, Gelbaya TA, Horne G, Fitzgerald CT, Pease EH, et al. The optimal length of ‘coasting protocol’ in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization. Hum Fertil (Camb). 2006;9:175–80.
    Ho Yuen B, Nguyen TA, Cheung AP, Leung PC: Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting. Fertil Steril. 2008.
    Moon HS, Joo BS, Moon SE, Lee SK, Kim KS, Koo JS. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. Fertil Steril. 2008;90:2172–8.
    Yilmaz N, Uygur D, Ozgu E, Batioglu S: Does coasting, a procedure to avoid ovarian hyperstimulation syndrome, affect assisted reproduction cycle outcome? Fertil Steril. 2009.
    Garcia-Velasco JA, Zuniga A, Pacheco A, Gomez R, Simon C, Remohi J, et al. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod. 2004;19:1530–8.
    D’Angelo A, Amso N: “Coasting” (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2002;CD002811.
    Huddleston HG, Racowsky C, Jackson KV, Fox JH, Ginsburg ES. Coasting vs. cryopreservation of all embryos for prevention of ovarian hyperstimulation syndrome in in vitro fertilization. Fertil Steril. 2008;90:1259–62.
    Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod. 2002;17:3027–32.
    Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study. Fertil Steril. 2007;88:982–5.
    Bellver J, Munoz EA, Ballesteros A, Soares SR, Bosch E, Simon C, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod. 2003;18:2283–8.
    Ando H, Furugori K, Shibata D, Harata T, Murata Y, Mizutani S. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod. 2003;18:1219–22.
    Ata B, Yakin K, Alatas C, Urman B. Dual renin-angiotensin blockage and total embryo cryopreservation is not a risk-free strategy in patients at high risk for ovarian hyperstimulation syndrome. Fertil Steril. 2008;90:531–6.
    Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147:5400–11.
    Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online. 2008;17:751–5.
    Varnagy A, Bodis J, Manfai Z, Wilhelm F, Busznyak C, Koppan M: Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril. 2009.
    Quintana R, Kopcow L, Marconi G, Young E, Yovanovich C, Paz DA. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil Steril. 2008;90:1511–6.
    Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007;14:640–9.
    Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril. 2004;82:841–6.
    Nargund G, Hutchison L, Scaramuzzi R, Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online. 2007;14:682–5.
    Group TERLS. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab. 2001;86:2607–18.
    Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91:365–71.
    Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009;25:60–6.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89:84–91.
    Manzanares MA, Gomez-Palomares JL, Ricciarelli E, Hernandez ER: Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril. 2009.
    Lanzendorf SE. Developmental potential of in vitro- and in vivo-matured human oocytes collected from stimulated and unstimulated ovaries. Fertil Steril. 2006;85:836–7.
    Suikkari AM. In-vitro maturation: its role in fertility treatment. Curr Opin Obstet Gynecol. 2008;20:242–8.
    Son WY, Chung JT, Demirtas E, Holzer H, Sylvestre C, Buckett W, et al. Comparison of in-vitro maturation cycles with and without in-vivo matured oocytes retrieved. Reprod Biomed Online. 2008;17:59–67.
    Son WY, Chung JT, Chian RC, Herrero B, Demirtas E, Elizur S, et al. A 38 h interval between hCG priming and oocyte retrieval increases in vivo and in vitro oocyte maturation rate in programmed IVM cycles. Hum Reprod. 2008;23:2010–6.